|
KMID : 0355220070320040449
|
|
Journal of Korean Academy Oral Medicine
2007 Volume.32 No. 4 p.449 ~ p.453
|
|
|
Clinical Considerations of Trigeminal Neuralgia
|
|
Jeon Young-Mi
Kwon Jeong-Seung
Tae Il-Ho
Choe Jong-Hun
Ahn Hyung-Joon
Shim Woo-Hyun
|
|
|
Abstract
|
|
|
Trigeminal neuralgia is defined as “a sudden, usually unilateral, brief stabbing recurrent pain in the distribution of one or more branches of the fifth cranial nerve” by the International Association for the Study of Pain(IASP). Trigeminal neuralgia is classified as an idiopathic trigeminal neuralgia with no apparent cause and a symptomatic trigeminal neuralgia which is caused by a structural lesion such as brain tumor. Over 80% of the tumors are meningioma, acoustic neuroma, and epidermoid tumors. Symptomatic trigeminal neuralgia can not be excluded even if old-aged patient does not have abnormal neurologic sign and symptom, and good response to pharmacotherapy. Therefore, initial examinations such as MRI or CT are essential to exclude symptomatic trigeminal neuralgia. When compared with CT, MRI, especially gadolinium enhanced MRI, has an increased sensitivity in the detection of intracranial lesions.
The most effective medical treatment of trigeminal neuralgia is carbamazepine. The most common side effects of carbamazepine include drowsiness, dizziness, unsteadiness, nausea, anorexia. Hepatotoxicity, bone marrow depression are the most feared side effect of carbamazepine therapy but occurs rarely. It require periodic complete blood cell counts as well as hepatic and renal function tests. It has been recommended that complete blood cell counts is done every 2 weeks for the first 2months and then quaterly thereafter. Oxcarbazepine can be used if neutropenia occurs.
|
|
|
KEYWORD
|
|
|
Trigeminal neuralgia, Symptomatic trigeminal neuralgia, Brain MRI, Carbamazepine, Oxcarbazepine
|
|
|
FullTexts / Linksout information
|
|
 
|
|
|
Listed journal information
|
|
|
|